Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Temsirolimus (Primary)
- Indications CNS cancer; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms TemPCNSL
- 14 Mar 2016 Status changed from recruiting to completed, as per results published in the Journal of Clinical Oncology.
- 14 Mar 2016 Results published in the Journal of Clinical Oncology
- 10 Apr 2013 Planned end date changed from 1 Mar 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.